NorthStar Medical Radioisotopes, LLC Announces Business Update and Commercial Progress on RadioGenix® System Launch
NorthStar Medical Radioisotopes , LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced a corporate update highlighting the continued commercial progress of its RadioGenix System following U.S. Food and Drug Administration (FDA) approval in February, 2018.
- NorthStar Medical Radioisotopes , LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced a corporate update highlighting the continued commercial progress of its RadioGenix System following U.S. Food and Drug Administration (FDA) approval in February, 2018.
- NorthStar is making important progress in achieving its vision to become a leading medical radioisotope production company:
NorthStar continues to successfully implement its carefully staged launch of the RadioGenix System. - To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Medical Radioisotopes, LLC at 1-844-438-6659; or FDA at 1-800-332-1088 or www.fda.gov/medwatch .
- Founded in 2006 and based in Beloit, Wis., NorthStar Medical Radioisotopes, LLC is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC.